Your browser is no longer supported. Please, upgrade your browser.
AZN [NASD]
AstraZeneca PLC
Index- P/E41.37 EPS (ttm)1.43 Insider Own0.50% Shs Outstand2.62B Perf Week-2.48%
Market Cap183.81B Forward P/E14.90 EPS next Y3.98 Insider Trans0.00% Shs Float2.62B Perf Month6.71%
Income3.77B PEG2.02 EPS next Q0.62 Inst Own15.10% Short Float0.27% Perf Quarter3.04%
Sales29.53B P/S6.22 EPS this Y137.20% Inst Trans0.86% Short Ratio0.77 Perf Half Y13.43%
Book/sh5.97 P/B9.93 EPS next Y21.71% ROA5.60% Target Price68.58 Perf Year11.80%
Cash/sh5.04 P/C11.76 EPS next 5Y20.50% ROE26.00% 52W Range46.48 - 61.34 Perf YTD18.60%
Dividend1.40 P/FCF107.87 EPS past 5Y1.70% ROI12.20% 52W High-3.34% Beta0.47
Dividend %2.36% Quick Ratio1.00 Sales past 5Y1.50% Gross Margin76.20% 52W Low27.56% ATR1.03
Employees76100 Current Ratio1.20 Sales Q/Q31.00% Oper. Margin19.20% RSI (14)49.54 Volatility1.15% 1.52%
OptionableYes Debt/Eq1.75 EPS Q/Q-27.50% Profit Margin12.80% Rel Volume0.45 Prev Close60.22
ShortableYes LT Debt/Eq1.57 EarningsNov 12 BMO Payout65.40% Avg Volume9.33M Price59.29
Recom1.60 SMA20-0.74% SMA501.23% SMA2008.20% Volume4,191,840 Change-1.54%
Aug-12-21Resumed JP Morgan Overweight
Apr-12-21Downgrade Argus Buy → Hold
Mar-16-21Upgrade Jefferies Hold → Buy
Feb-25-21Upgrade UBS Neutral → Buy
Jan-15-21Initiated Deutsche Bank Buy
Dec-07-20Upgrade Morgan Stanley Equal-Weight → Overweight
Nov-30-20Upgrade UBS Sell → Neutral
Nov-11-20Upgrade HSBC Securities Reduce → Hold
Sep-29-20Initiated Berenberg Buy
Nov-22-19Initiated SVB Leerink Outperform
Oct-25-19Upgrade Liberum Hold → Buy
Apr-02-19Downgrade UBS Neutral → Sell
Feb-05-19Initiated Exane BNP Paribas Outperform
Jan-25-19Upgrade Shore Capital Hold → Buy
Dec-11-18Resumed Jefferies Hold
Oct-09-18Initiated Guggenheim Buy
Aug-16-18Downgrade Jefferies Buy → Hold
Mar-19-18Upgrade Jefferies Hold → Buy
Feb-06-18Reiterated Leerink Partners Mkt Perform $36 → $38
Feb-05-18Reiterated Bernstein Outperform $40 → $42
Oct-18-21 05:16AM  
04:23AM  
03:47AM  
01:35AM  
01:31AM  
Oct-16-21 08:01AM  
Oct-15-21 07:02PM  
02:14PM  
11:04AM  
07:44AM  
07:33AM  
07:00AM  
Oct-14-21 03:20PM  
02:37PM  
10:00AM  
08:10AM  
06:00AM  
Oct-13-21 08:12PM  
07:15PM  
02:32PM  
11:38AM  
Oct-12-21 07:46PM  
02:30PM  
09:31AM  
Oct-11-21 04:18PM  
03:10PM  
11:13AM  
10:43AM  
07:53AM  
02:52AM  
Oct-08-21 09:52PM  
02:32PM  
08:33AM  
08:08AM  
07:00AM  
05:36AM  
Oct-07-21 08:35PM  
05:52PM  
01:48PM  
Oct-06-21 02:32PM  
01:07PM  
Oct-05-21 06:02PM  
12:07PM  
10:37AM  
10:20AM  
09:42AM  
08:48AM  
08:01AM  
07:00AM  
06:42AM  
06:30AM  
05:17AM  
02:42AM  
02:03AM  
Oct-04-21 07:00AM  
07:00AM  
Oct-01-21 10:31AM  
09:18AM  
09:11AM  
08:47AM  
Sep-30-21 03:06PM  
02:52PM  
11:47AM  
10:47AM  
10:46AM  
07:41AM  
07:33AM  
01:21AM  
Sep-29-21 11:57PM  
05:00PM  
02:28PM  
02:06PM  
10:05AM  
09:33AM  
08:59AM  
08:21AM  
07:00AM  
03:35AM  
02:34AM  
Sep-28-21 09:33AM  
09:10AM  
08:13AM  
03:44AM  
Sep-27-21 02:36PM  
02:01PM  
10:46AM  
10:25AM  
07:00AM  
06:00AM  
05:14AM  
03:45AM  
01:00AM  
Sep-24-21 02:07PM  
02:02PM  
01:06PM  
11:02AM  
08:27AM  
06:53AM  
06:45AM  
06:00AM  
AstraZeneca PLC discovers, develops, manufactures, and commercializes prescription medicines in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infection, neuroscience, and gastroenterology worldwide. The company's marketed products include Tagrisso, Lynparza, Imfinzi, Enhertu, Koselugo, Lumoxiti, Equidacent, Zoladex, Faslodex, Iressa, Arimidex, Casodex/Cosudex, and others for oncology diseases; Onglyza, Bydureon, Lokelma, Byetta, Qtern, Symlin, and others for cardiovascular, renal, and metabolism diseases; and Symbicort, Pulmicort, Fasenra, Daliresp/Daxas, Duaklir, Tudorza/Eklira, Bevespi, Breztri, Anifrolumab, and others for respiratory and immunology diseases. It also offers other medicines and COVID-19 products, including Synagis, Fluenz Tetra/FluMist Quadrivalent, Seroquel IR/Seroquel XR, Vimovo, Movantik/Moventig, Nexium, Losec/Prilosec, and COVID-19 Vaccine AstraZeneca. The company serves primary care and specialty care physicians through distributors and local representative offices. It has a collaboration agreement with Daiichi Sankyo to develop and commercialize DS-1062 for the treatment of trophoblast cell-surface antigen 2 (TROP2) tumor; AliveCor, Inc. to develop non-invasive potassium monitoring solutions; Massachusetts General Hospital to accelerate digital health solutions; Sanguina on smartphone application study for hemoglobin management in patients with anemia of chronic kidney disease; Alchemab to enhance prostate cancer research; and Proteros biostructures GmbH to discover and develop novel small molecules for the treatment of various types of cancer. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. It has a collaboration agreement with Regeneron Pharmaceuticals, Inc. to research, develop, and commercialize small molecule medicines for obesity. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.